Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

4 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Registration and Randomization Form (HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26)

- 20/09/2021 - 1 Formulaire, 4 Groupes Item, 39 Eléments de données, 1 Langue
Groupes Item: Patient data, Patient consent, Eligibility, Data from HOVON data center
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5) With friendly permission of HOVON-Group - Prof. G. Ossenkoppele

Cytogenetic and FISH Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Cytogenetic and FISH Form

- 11/02/2016 - 1 Formulaire, 5 Groupes Item, 31 Eléments de données, 1 Langue
Groupes Item: Cytogenetic and FISH Form, Comment Of The Reviewer, Interphase FISH, Metaphase FISH, Comment Of The Reviewer
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)

Chemotherapy Evaluation Form HOVON 132 AML/SAKK 30/13 EudraCT 2013-002843-26 - Chemotherapy Evaluation Form

- 11/02/2016 - 1 Formulaire, 4 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Cycle, Bone Marrow Evaluation, Response Evaluation, Comments
Randomized study with a run-in dose-selection phase to assess the added value of Lenalidomide in combination with standard remission-induction chemotherapy and post-remission treatment in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or high risk myelodysplasia (MDS) (IPSS-R risk score> 4.5)

Eligibility Active Systemic Onset JIA NCT00570661 - Eligibility Active Systemic NCT00570661

- 30/11/2015 - 1 Formulaire, 2 Groupes Item, 32 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Phase II, Open Label, International, Multicentre Clinical Trial to Investigate Safety and Efficacy of Oral ITF2357 in Patients With Active Systemic Onset Juvenile Idiopathic Arthritis (SOJIA); ODM derived from: https://clinicaltrials.gov/show/NCT00570661

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial